Viaud S.,French Institute of Health and Medical Research |
Viaud S.,Faculte Of Medecine Of Luniversite Paris Sud Xi |
Ploix S.,French Institute of Health and Medical Research |
Lapierre V.,French Institute of Health and Medical Research |
And 18 more authors.
Journal of Immunotherapy | Year: 2011
Dendritic cell-derived exosomes (Dex) are nanovesicles bearing major histocompatibility complexes promoting T-cell-dependent antitumor effects in mice. Two phase I clinical trials aimed at vaccinating cancer patients with peptide-pulsed Dex have shown the feasibility and safety of inoculating clinical-grade Dex, but have failed to show their immunizing capacity. These low immunogenic capacities have led us to develop second-generation Dex with enhanced immunostimulatory properties. Here, we show that interferon-γ is a key cytokine conditioning the dendritic cell to induce the expression of CD40, CD80, CD86, and CD54 on Dex, endowing them with direct and potent peptide-dependent CD8 T-cell-triggering potential in vitro and in vivo. In this study, we describe the clinical grade process to manufacture large-scale interferon-γ-Dex vaccines and their quality control parameters currently used in a phase II trial. © 2010 by Lippincott Williams & Wilkins. Source